U.S. Patent and Trademark Office Allows microRNA Mimic Composition of
AUSTIN, Texas--(BUSINESS WIRE)--
Mirna Therapeutics, Inc., a private biotechnology company pioneering
microRNA (miRNA) replacement therapies for cancer, announced today the
allowance of key claims in U.S. Patent Application No. 11/837,487
entitled “Method and compositions involving miRNA and miRNA inhibitor
molecules.” The allowed claims describe multiple chemistries and
structures used in therapeutic miRNA mimics, including the one used in
MRX34, the Company’s lead clinical candidate. The composition of matter
claims complement other Mirna patents previously issued by the U.S.
Patent and Trademark Office, which relate to the therapeutic use of
fifteen miRNAs in the treatment of various cancers.
Mirna is currently conducting a Phase 1 clinical trial of MRX34, a
miR-34-based therapy and the first miRNA mimic to advance into a human
clinical trial. The Phase 1 trial is treating patients with unresectable
primary liver cancer or metastatic cancer with liver involvement. The
Company expects to complete the clinical trial late 2014.
“In addition to multiple patents in our portfolio issued already in U.S.
and Europe, this patent provides further significant intellectual
property protection for the miRNA in Mirna’s lead product candidate
MRX34 and that of other miRNA mimics in our pipeline,” said Dr. Paul
Lammers, Mirna’s President and CEO. “The allowed claims increase the
value of MRX34 as well as additional earlier stage assets in our
pipeline and, importantly, these claims strengthen our position as a
leading miRNA therapeutics company.”
Mirna’s research is in part supported by a commercialization grant from
the Cancer Prevention and Research Institute of Texas (CPRIT).
About Liver Cancer
Liver cancer is the fifth most common cancer worldwide and the third
leading cause of cancer death. The World Health Organization estimates
that there are over 600,000 new cases diagnosed annually which results
in more than 90 percent mortality. The annual incidence rate in the U.S.
is estimated to be approximately 20,000 patients.
MRX34 is the first of a series of clinical therapeutic candidates from
Mirna Therapeutics designed to mimic the activity of a human microRNA
(miRNA). MRX34 is a liposome-formulated mimic of the tumor suppressor
miRNA, miR-34, which is lost or expressed at reduced levels in most
solid and liquid tumors. It functions within the p53 pathway and
inhibits cancer cell growth by repressing MYC, MET, BCL2, ß-catenin, and
other oncogenes. The miR-34 mimic induces cell cycle arrest, senescence
and cell death. It also interferes with the viability of cancer stem
cells, creates a barrier to metastasis, and sensitizes cancer cells to
About Mirna Therapeutics
Mirna Therapeutics, Inc. (Mirna) is a biotechnology company focused on
the development and commercialization of miRNA therapeutics. The Company
has a foundational intellectual property portfolio on the therapeutic
use of miRNAs developed by its own scientists as well as in-licensed
from other institutions. Mirna’s IP portfolio contains more than 300
miRNAs with applications in oncology and other diseases.
Oncology-directed miRNAs include those that are key tumor suppressors in
cancer, such as miR-34 and let-7, which have been shown to block tumor
growth in a number of different preclinical animal studies. The Company,
founded in 2007 and located in Austin, Texas, has received significant
funding from Sofinnova Ventures, New Enterprise Associates, Pfizer
Venture Investments and other private investors, as well as the State of
Texas, both through the State’s Emerging Technology Fund and from the
Cancer Prevention and Research Institute of Texas (CPRIT). For more
information, visit www.mirnarx.com.
Mirna Therapeutics, Inc.
Paul Lammers, M.D., M.Sc., 512-901-0909
Source: Mirna Therapeutics, Inc.